Please login to the form below
IBD
This page shows the latest IBD news and features for those working in and with pharma, biotech and healthcare.
BMS to test Vedanta’s bacterial therapy with Opdivo
The two companies have started treating patients in a phase 1 trial of VE202, another bacterial consortium aimed at treating inflammatory bowel disease (IBD). ... VE202 is based on the idea that IBD patients are deficient in certain Clostridia species in
Latest news
-
Communiqué: big wins for obesity and sugar tax campaigners
Specialist healthcare communications group Sciterion (pictured below) won the Excellence in Communications via a Live Event or Stand-Alone Activity accolade for its Live Multi-site National IBD Meeting. ... Meanwhile, Aurora Healthcare Communications’
-
Daily Brief: NICE says no to Zytiga, Genentech and UK biotech sign microbiome deal
therapies. Genentech is tapping into the Cambridge, UK-based company’s expertise by using its precision metagenomics microbiome platform to analyse patient samples from clinical trials of its investigational IBD medicines. ... This will allow
-
Pfizer’s Xeljanz picks up a third indication in the US
that could strengthen Pfizer’s stance in the inflammatory bowel disease (IBD) market. ... Continuing this trend, Xeljanz is also the first and only JAK inhibitor approved in the US to treat UC, and an approval in the IBD therapy area for this
-
Gilead and Verily team up to map inflammatory diseases
Computational analysis could provide deeper understanding of disease
-
J&J takes option on Theravance’s JAK drug in $1bn deal
TD-1473 has potential treating ulcerative colitis, Crohn’s and IBD patients. Johnson &Johnson is paying $100m upfront for opt-in rights to a JAK inhibitor developed by Theravance, with another
More from news
Approximately 11 fully matching, plus 27 partially matching documents found.
Latest Intelligence
-
Deal Watch February 2017
The deal also includes a licence to AKB-5169 (formerly JNJ5169), an oral, preclinical stage compound for inflammatory bowel disease (IBD). . ... Joint venture. 286.3. Janssen/ Akebia Therapeutics. HIF-targeting candidates inc AKB-5169 for IBD (pc)
-
Deal Watch June 2016
IBD). PF-00547659 targets a gastrointestinal endothelial adhesion molecule known as mucosal addressin cell adhesion molecule 1 (MAdCAM-1) that binds to the α4β7 integrin on lymphocytes.
-
Deal Watch October 2015
Janssen's partnership with Canadian biotech enGene, facilitated through J&J Innovation, brings gene therapies for inflammatory bowel disease (IBD) and includes an undisclosed upfront payment and equity investment, R&D ... Research collaboration, option,
-
Pharma deals in June 2015
the treatment of inflammatory bowel disease (IBD). ... 130. Lycera Corporation/ Celgene Corporation. Orally bioavailable RORgamma agonists for ex vivo use lead programme, LYC-30937 (oral gut-directed ATPase modulator for IBD, p1).
-
Getting real about patient support
opposed to a series of acute episodes (such as in asthma, COPD or IBD).
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Latest appointments
-
Takeda strengthens leadership team with business unit director
Takeda UK has appointed Craig Adkins as its new business unit director for irritable bowel disease (IBD). .
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
Latest from PMHub
-
IBD Registry appoints first CEO
The IBD Registry is familiar to many as the first UK-wide collection of anonymised adult and paediatric IBD data for prospective audit and research. ... Liz brings to the IBD Registry 20 years of executive and senior management experience from the
-
Pharma and NHS working together for patients - the IBD Registry Industry Working Group
Recently, we spoke to members of the IBD Registry Industry Working Group about what they’ve achieved in their first year, and whether or not it’s been worthwhile.
-
Joined-up thinking on anaemia
Iron deficiency anaemia is very common in inflammatory bowel disease (IBD) and can seriously reduce people’s quality of life, but it’s often under-treated. ... The partners share resources and skills and the project is the first to use the IBD
-
Innovation in pharma: the highs and lows of the current healthcare economy
the use of biosimilars used to fund additional specialist IBD (inflammatory bowel disease) nurses to improve standards of care in areas where service support is thin on the ground.
-
Biosimilars: Getting the flock to market
could halve the cost of IBD treatment.
More from PMHub
Approximately 3 fully matching, plus 16 partially matching documents found.
Featured jobs
-
Associate Medical Director
-
Excellent PTO, bonus and 401k package
- Business Development Director – Health Education
-
excellent commission
-
Medical (Scientific) Director
-
£120, 000 benefits
-
Experienced Medical Writers
-
Competitive Salary and Benefits
- Senior Account Executive with progression to Account Manager, Me...
-
Excellent package
- Manager - Immunology, Therapeutic Area Communications & Publ...
-
Competitive Salary Offered
- Account Manager- Healthcare Advertising
-
Negotiable
-
Account Manager
-
Negotiable
-
Account Director
-
Competitive Salary Offered
- CALLING ALL SENIOR HEALTHCARE PR FREELANCERS!!!!! ACCOUNT DIRECT...
-
EXCELLENT DAY RATES AVAILABLE
- Account Executive/ Senior Account Executive
-
competitive Salary Offfered
-
Medical Writer
-
Bonus Scheme, PTO &Private Healthcare
-
Medical Writer
-
Salary TBC
-
Senior Account Manager
-
Competitive Salary Offered
-
Associate Director
-
£75, 000-90, 000
-
Account Manager / Account Director
-
Competative
Subscribe to our email news alerts
PMHub
huumun formerly PharmiWeb Solutions
huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...
Latest intelligence
- AstraZeneca’s oncology renaissance
- Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
- Navigating the antibiotic resistance crisis
- Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
- Combined immunotherapies – potential and pitfalls
- ‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Quick links
Infographics
